leisure time -WSS

leisure time

author：leisure time 2025-09-30 18:53:48 - browse：1

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： How climate

WSS

Researchers explore possible ties between long Covid, menopause

NIH confirmation hearing shows politicization of research

Pfizer highlights cancer drugs it thinks could reignite investor interest

STAT Summit: Biotech founders on deal

Hospital price transparency does save money, advocate argues

How to address the problem of discarded donor organs

Wikipedia

leisure time

focus

Bright Health sells Medicare Advantage business to Molina

International team creates first chimeric human

After affirmative action ruling, medical educators look to 'holistic review'

In search for therapies for solid tumors, companies turn to claudin

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Solve the antibiotic resistance crisis with preventive drugs

New air purifier tech could be key to improving indoor air quality

Senate committee scrutinizes Medicare Advantage brokers

How to save PrEP access — and even expand it

CEOs share strategies for surviving biotech slump

leisure time

Why getting cancer drugs just got harder for rural patients

International team creates first chimeric human

An inside look at PIPEs, biotech's buzzy new financing tool

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Lawmakers consider Medicare pay reforms for doctors

2023 STAT Wunderkinds: get to know the winners

Wikipedia

leisure time

hotspot

leisure time